Through genomic profiling analysis of the designated 324 genes of the patient’s tumor samples by using the FoundationOne CDx® (Foundation Medicine Inc., MA, USA) oncology panel, two pathogenic variants in RAD51D (splicing variant) and TP53 (missense variant) and intermediate amplifications of four genes were detected (Table 1). This evidence concerns the gene RAD51D and neoplasm.